Hi-Tech Pharmacal Co. (HITK) Tops Q2 EPS by 7c

December 6, 2012 7:09 AM EST
Hi-Tech Pharmacal Co. (NASDAQ: HITK) reported Q2 EPS of $0.66, $0.07 better than the analyst estimate of $0.59. Revenue for the quarter came in at $57.54 million versus the consensus estimate of $56.89 million.

For earnings history and earnings-related data on Hi-Tech Pharmacal Co. (HITK) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment